Table I.
Chemicals and cytokines used in the stated culture conditions.
| Cytokines added | ||||||
|---|---|---|---|---|---|---|
| Condition | Addition at day 0, 3, 6 | Day (6/7) | Day (5/6/7) | Day of harvest |
||
| 1 | Immature DC | GM-CSF (500 IU/mL) | IL-4 (20 ng/mL) | 9 | ||
| 2 | Mature DC | GM-CSF (500 IU/mL) | IL-4 (20 ng/mL) | TNF-α (50 ng/mL) (6) | 9 | |
| 3 | Mature DC | GM-CSF (500 IU/mL) | IL-4 (20 ng/mL) | TNF-α (50 ng/mL) (7) | PGE2 (1 µg/mL) (7) | 8 |
| 4 | Mature DC | GM-CSF (1000 IU/mL) | IL-4 (40 ng/mL) | TNF-α (50 ng/mL) (6) | PGE2 (1 µg/mL) (6) | 7 |
| 5 | Polarized DC | GM-CSF (500 IU/mL) | IL-4 (20 ng/mL) | LPS (250 ng/mL) (6) | IFN-γ (0.5 µg/mL) (5) | 7 |
| 6 | Mature DC | GM-CSF (500 IU/mL) | IL-4 (20 ng/mL) | TNF-α (50 ng/mL) (6) | Sunitinib (100 ng/mL) (6) | 9 |
Suppliers: IL-4, TNF-α (R&D Systems, Minneapolis, MN, USA), GM-CSF (Berlex, Bayer Healthcare, Seattle, WA, USA), IFN-γ, PGE2 (Sigma Aldrich, St. Louis, MO, USA), LPS (List Lab, Gainesville, FL, USA) and sunitinib (Pfizer, New York, NY, USA).